Fluvoxamine

Luvox
Fluvoxamine, sold under the brand name Luvox among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class which is used primarily for the treatment of obsessive–compulsive disorder (OCD).wikipedia
190 Related Articles

Antidepressant

antidepressantsanti-depressantanti-depressants
Fluvoxamine, sold under the brand name Luvox among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class which is used primarily for the treatment of obsessive–compulsive disorder (OCD).
Sertraline and fluvoxamine extended release were later approved for it too while escitalopram is used off label with acceptable efficacy.

Selective serotonin reuptake inhibitor

SSRIselective serotonin reuptake inhibitorsSSRIs
Fluvoxamine, sold under the brand name Luvox among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class which is used primarily for the treatment of obsessive–compulsive disorder (OCD).
Paroxetine was the first drug to be approved for social anxiety disorder and it is considered effective for this disorder, sertraline and fluvoxamine were later approved for it too, escitalopram and citalopram are used off label with acceptable efficacy, while fluoxetine is not considered to be effective for this disorder.

Social anxiety disorder

social phobiaAnthropophobiasociophobia
It is also used to treat depression and anxiety disorders, such as panic disorder, social anxiety disorder, and post-traumatic stress disorder.
Paroxetine, sertraline and fluvoxamine are three SSRIs that have been approved by the FDA to treat social anxiety disorder.

Clomipramine

Anafranilchlorimipramineclomipramine hydrochloride
In a meta-analysis of various trials involving fluoxetine (Prozac), fluvoxamine (Luvox), and sertraline (Zoloft) to test their relative efficacies in treating OCD, clomipramine was found to be the most effective.

Cytochrome P450

cytochrome P450 oxidaseP450CYP450
Fluvoxamine inhibits the following cytochrome P450 enzymes:

Alprazolam

XanaxCalmaxXanny
The plasma levels of oxidatively metabolized benzodiazepines (e.g., triazolam, midazolam, alprazolam and diazepam) are likely to be increased when co-administered with fluvoxamine.
Combining CYP3A4 inhibitors such as cimetidine, erythromycin, norfluoxetine, fluvoxamine, itraconazole, ketoconazole, nefazodone, propoxyphene, and ritonavir delay the hepatic clearance of alprazolam, which may result in its accumulation and increased severity of its side effects.

Ramelteon

RameltonRozerem
Fluvoxamine and ramelteon coadministration is not indicated.
When coadministered with ramelteon, fluvoxamine (strong CYP1A2 inhibitor) increased AUC approximately 190-fold, and the C max increased approximately 70-fold, compared to ramelteon administered alone.

Pharmacokinetics

pharmacokineticsteady-stateSteady-state levels
Fluvoxamine seriously affects the pharmacokinetics of tizanidine and increases the intensity and duration of its effects.

Diazepam

ValiumDizacCANA
The plasma levels of oxidatively metabolized benzodiazepines (e.g., triazolam, midazolam, alprazolam and diazepam) are likely to be increased when co-administered with fluvoxamine.

CYP1A2

1A2cytochrome p-450 cyp1a22
Because of the potentially hazardous consequences, the concomitant use of tizanidine with fluvoxamine, or other potent inhibitors of CYP1A2, should be avoided.

Aripiprazole

AbilifyAripriprazole
There are interactions with fluoxetine and paroxetine and lesser interactions with sertraline, escitalopram, citalopram and fluvoxamine, which inhibit CYP2D6, for which aripiprazole is a substrate.

Caffeine

caffeinatedHealth effects of caffeineNo-Doz
The antidepressant fluvoxamine (Luvox) reduces the clearance of caffeine by more than 90%, and increases its elimination half-life more than tenfold; from 4.9 hours to 56 hours.

Sertraline

ZoloftLustralSertraline Hydrochloride
Comparative clinical trials demonstrated that sertraline is similar in efficacy against depression to moclobemide, nefazodone, escitalopram, bupropion, citalopram, fluvoxamine, paroxetine, and mirtazapine.

Agomelatine

Valdoxan
Inhibitors of these enzymes, e.g. the SSRI antidepressant fluvoxamine, reduce its clearance and can therefore lead to an increase in agomelatine exposure.

Tizanidine

Zanaflex
Fluvoxamine seriously affects the pharmacokinetics of tizanidine and increases the intensity and duration of its effects. Because of the potentially hazardous consequences, the concomitant use of tizanidine with fluvoxamine, or other potent inhibitors of CYP1A2, should be avoided.
Concomitant use of tizanidine with fluvoxamine, a potent CYP1A2 inhibitor in humans, resulted in a 33-fold increase in the tizanidine AUC (plasma drug concentration-time curve).

Tamoxifen

NolvadexTamoxifen citratehydroxytamoxifen
Patients taking the SSRIs; Celexa (citalopram), Lexapro (escitalopram), and Luvox (fluvoxamine), did not have an increased risk of recurrence, due to their lack of competitive metabolism for the CYP2D6 enzyme.

Olanzapine

ZyprexaZyprexa (olanzapine)adverse effects
Drugs or agents that increase the activity of the enzyme CYP1A2, notably tobacco smoke, may significantly increase hepatic first-pass clearance of olanzapine; conversely, drugs which inhibit CYP1A2 activity (examples: ciprofloxacin, fluvoxamine) may reduce olanzapine clearance.

Theophylline

Theo-DurAccurbronAerolate
Theophylline should not be used in combination with the SSRI fluvoxamine.

Chlorpromazine

ThorazineLargactilchlorpromazine hydrochloride
Cotreatment with CYP1A2 inhibitors like ciprofloxacin, fluvoxamine or vemurafenib can reduce chlorpromazine clearance and hence increase exposure and potentially also adverse effects.

Clozapine

ClozarilclonazepamFazaclo
Fluvoxamine inhibits the metabolism of clozapine leading to significantly increased blood levels of clozapine.

Fluoxetine

ProzacProzakSarafem
Contrary to Fluoxetine, Fluvoxamine metabolites are inactive, without a significant effect on serotonin or norepinephrine uptake.
In addition, fluoxetine has been found to act as an agonist of the σ 1 -receptor, with a potency greater than that of citalopram but less than that of fluvoxamine.